Leishmaniasis is considered as a zoonotic infection and neglected tropical disease.
Leishmania
treatment is not totally successful and imposes high expenditures, especially in developing countries. Since the natural infection leads to the robust immunity in most of the human cases, many bodies of research have been focusing on
Leishmania
vaccines, being capable to control
Leishmania
infection. First generation vaccines (such as Leishmune
®
and CaniLeish
®
) have proved robust protective immunity in dogs. In human, recombinant vaccines, including Leish-F1 could confer some degrees of protective immunity against natural infection. Recently, ChAd63-KH DNA vaccine has been accomplished in providing prevention against
Leishmania
infection; however, this vaccine should be further evaluated in other clinical trials.
Phlebotomus papatsi North Africa, the Middle East, central Asia and the Indian subcontinent L. tropica LCL Human Rock hyraxes Unknown animals P. sergenti North Africa, the Middle East, central Asia and the Indian subcontinent
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.